ESR1 mutant meme kanserinde en çok atıf alan 100 makale: bibliyometrik bir analiz

Abstract

ölümlerin başlıca nedenlerinden biridir. Meme kanseri olgularının yaklaşık %70’i östrojen reseptörü pozitif (ER+) olup bu hastaların büyük bir kısmı hormon temelli tedavilerden fayda görmektedir. Ancak başlangıçta alınan yanıtlara rağmen, özellikle metastatik evrede birçok hastada zamanla tedavi direnci gelişmektedir. Bu çalışmanın amacı, ESR1 mutasyonlu meme kanseri ile ilişkili en çok atıf alan 100 özgün araştırma makalesini belirlemek ve analiz ederek, bu alandaki yayın eğilimleri, önde gelen katkı sağlayıcılar ve tematik odaklar hakkında bilgi sunmaktır. Gereç ve Yöntemler: 20 Mayıs 2025 tarihinde Web of Science Core Collection (WoSCC) kullanılarak sistematik bir tarama yapılmıştır. Meme kanserinde ESR1 mutasyonları ile ilişkili, en çok atıf alan 100 özgün araştırma makalesi atıf sayılarına göre seçilmiş; özgün olmayan ve İngilizce dışındaki yayınlar çalışma dışı bırakılmıştır. Bibliyometrik haritalama VOSviewer yazılımı (v1.6.10) kullanılarak gerçekleştirilmiştir. Bulgular: 2007–2024 yılları arasında yayımlanan toplam 100 makale analiz edilmiştir. En çok atıf alan makale 919 atıf almıştır. Yayınların ve atıfların büyük çoğunluğu Amerika Birleşik Devletleri kaynaklıdır. Nature Genetics makale başına en yüksek atıf oranına sahip dergi olurken, Clinical Cancer Research en fazla üst düzey atıf alan makaleyi yayımlayan dergi olmuştur. En sık kullanılan anahtar kelimeler arasında “ESR1”, “meme kanseri” ve “direnç” yer almıştır. Sonuç: Bu bibliyometrik analiz, meme kanserinde ESR1 mutasyonlarına ilişkin temel ve gelişmekte olan literatürü ortaya koymaktadır. Alandaki kritik çalışmaları belirleyerek ve araştırma alanının gelişimini haritalandırarak araştırmacılar ve klinisyenler için değerli bir başvuru kaynağı sunmaktadır.

Keywords

• bibliyometrik analiz
• meme kanseri
• endokrin direnç
• östrojen reseptör 1
• esr1 mutasyonu

The 100 most cited articles in ESR1 mutant breast cancer: a bibliometric analysis

Abstract

Aim: Breast cancer is the most frequently diagnosed cancer and one of the main causes of cancer related death in women worldwide. Around 70% of breast cancer cases are estrogen receptor positive (ER+), and many of these patients benefit from hormone based treatments. However, despite initial responses, a large number of patients eventually develop resistance, especially in the metastatic stage .This study aims to identify and analyze the 100 most cited original research articles related to ESR1-mutant breast cancer, providing insights into publication trends, leading contributors, and thematic focuses in this growing field. Material and Methods: A systematic search was conducted on May 20, 2025, using the Web of Science Core Collection (WoSCC). The top 100 cited original research articles related to ESR1 mutations in breast cancer were selected based on citation count, excluding non-original and non-English papers. Bibliometric mapping was performed using VOSviewer software (v1.6.10). Results: A total of 100 articles published between 2007 and 2024 were analyzed. The most cited article received 919 citations. Most publications and citations originated from the United States. Nature Genetics had the highest citation rate per article, while Clinical Cancer Research had the largest number of top-cited articles. Common keywords included “ESR1,” “breast cancer,” and “resistance.” Conclusion: This bibliometric analysis highlights the foundational and emerging literature on ESR1 mutations in breast cancer. It provides a valuable reference for researchers and clinicians by identifying pivotal studies and mapping the development of this research domain.

Keywords

• bibliometric analysis
• breast cancer
• endocrine resistance
• estrogen receptor 1
• esr1 mutation

Ethical Statement

Ethical approval was not required for this study because it was based on publicly available bibliographic data and did not involve human participants or patient data.

References

1. Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin 2025; 75: 10-45.
2. Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 2015; 12: 573-83.
3. Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 2021; 23: 85.
4. Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013; 45: 1446-51.
5. Donthu N, Kumar S, Mukherjee D, Pandey N, Lim WM. How to conduct a bibliometric analysis: An overview and guidelines. J Bus Res 2021; 133: 285-96.
6. Toy W, Shen Y, Won H, Green B, Sakr RA, Will M et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet 2013; 45: 1439-45.
7. Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M et al. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer. J Clin Oncol 2016; 34: 2961-8.
8. Li S, Shen D, Shao J, Crowder R, Liu W, Prat A et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 2013; 4: 1116-30.

9. Page K, Martinson LJ, Fernandez-Garcia D, Hills A, Gleason KLT, Gray MC et al. Circulating Tumor DNA Profiling From Breast Cancer Screening Through to Metastatic Disease. JCO Precis Oncol 2021; 5: PO.20.00522.
10. Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Inao T, Sueta A, Fujiwara S et al. Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget 2016; 7: 32504-18.
11. Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM et al. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res 2014; 20: 1757-67.
12. Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D et al. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol 2016; 2: 1310-5.
13. Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F et al. Elacestrant Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol 2022; 40: 3246-56.
14. Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N et al. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell 2018; 34: 427-38.
15. Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C et al. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in ER-Positive, HER2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. J Clin Oncol 2024; 42: 4173-86.